Legal & General Group Plc Buys 23,577 Shares of Immunocore Holdings PLC Sponsored ADR $IMCR

Legal & General Group Plc boosted its holdings in shares of Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR) by 18.7% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 149,333 shares of the company’s stock after buying an additional 23,577 shares during the period. Legal & General Group Plc owned approximately 0.30% of Immunocore worth $5,183,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also added to or reduced their stakes in IMCR. Leonteq Securities AG purchased a new stake in Immunocore during the 4th quarter valued at about $30,000. Mirae Asset Global Investments Co. Ltd. grew its stake in Immunocore by 37.0% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,120 shares of the company’s stock valued at $74,000 after purchasing an additional 572 shares during the last quarter. Osaic Holdings Inc. grew its stake in Immunocore by 117.4% during the 2nd quarter. Osaic Holdings Inc. now owns 3,148 shares of the company’s stock valued at $97,000 after purchasing an additional 1,700 shares during the last quarter. State of Tennessee Department of Treasury purchased a new stake in Immunocore during the 2nd quarter valued at about $132,000. Finally, JT Stratford LLC purchased a new stake in Immunocore during the 3rd quarter valued at about $210,000. Hedge funds and other institutional investors own 84.50% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts have weighed in on the company. Wall Street Zen upgraded Immunocore from a “hold” rating to a “buy” rating in a research note on Saturday, May 9th. HC Wainwright reiterated a “buy” rating and set a $100.00 price target on shares of Immunocore in a research note on Monday, April 20th. Mizuho set a $38.00 price target on Immunocore in a research note on Thursday, February 19th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Immunocore in a research note on Tuesday, April 21st. Finally, Jefferies Financial Group downgraded Immunocore from a “buy” rating to a “hold” rating and dropped their price target for the company from $48.00 to $33.00 in a research note on Monday, March 16th. One analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $56.71.

Immunocore Stock Performance

Shares of Immunocore stock opened at $28.29 on Monday. The firm has a market capitalization of $1.43 billion, a price-to-earnings ratio of -51.44 and a beta of 0.74. Immunocore Holdings PLC Sponsored ADR has a fifty-two week low of $27.56 and a fifty-two week high of $40.71. The company has a debt-to-equity ratio of 1.00, a quick ratio of 4.15 and a current ratio of 4.18. The stock has a 50 day moving average of $29.77 and a 200 day moving average of $32.65.

Immunocore (NASDAQ:IMCR) last announced its quarterly earnings data on Wednesday, May 6th. The company reported $0.25 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.26) by $0.51. The business had revenue of $106.68 million for the quarter, compared to analysts’ expectations of $145.20 million. Immunocore had a negative return on equity of 7.07% and a negative net margin of 6.68%.The company’s revenue for the quarter was up 13.6% compared to the same quarter last year. During the same period last year, the firm earned $0.10 earnings per share. As a group, research analysts predict that Immunocore Holdings PLC Sponsored ADR will post 0.06 earnings per share for the current year.

About Immunocore

Immunocore plc is a clinical‐stage biotechnology company focused on the development of novel immunotherapies that harness the body’s own T‐cell response to treat cancer and infectious diseases. The company’s proprietary ImmTAC (immune mobilising monoclonal T‐cell receptors against cancer) platform utilizes engineered, soluble T‐cell receptor (TCR) molecules designed to recognise intracellular peptide–HLA complexes. By redirecting and activating T cells against disease‐associated targets, Immunocore aims to address malignancies and persistent viral infections with high unmet medical need.

The company’s most advanced candidate, tebentafusp, is a bispecific ImmTAC molecule that targets gp100, a melanoma‐associated antigen, and has received regulatory approval for the treatment of metastatic uveal melanoma.